RecruitingNCT07598747

Prospective Study for the Development, Validation and Confirmation of a Multi-Cancer Early Detection Platform Through Whole-Genome Sequencing Analysis of Circulating DNA in Cancer and Non-Cancer Subjects


Sponsor

Chang Gon Kim

Enrollment

6,000 participants

Start Date

Oct 14, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This is a prospective, multi-center clinical study of Multi-Cancer Early Detection (MCED) testing in cancer patients and healthy volunteers. This study was designed to establish a clinical and molecular database using circulating DNA from both cancer patients and non-cancer participants, advance and validate an artificial intelligence platform capable of detecting various types of cancer at an early stage, and evaluate its performance.


Eligibility

Min Age: 19 Years

Inclusion Criteria8

  • Adults aged 19 years or older
  • Individuals who understand the study and voluntarily provide informed consent.
  • (only for cancer participants) Participants with newly diagnosed solid tumors (Stage I-IV, including brain tumors) or hematologic malignancies who:
  • Have a histologically confirmed diagnosis (including bone marrow biopsy), or
  • Are highly suspected of having cancer based on clinical and/or radiologic evaluation and are scheduled for surgical resection after blood collection; and
  • Have not yet initiated any treatment (chemotherapy, targeted therapy, hormonal therapy, immunotherapy, radiotherapy, surgical resection, etc.).
  • (only for non-cancer participants) Individuals with no prior history of cancer.
  • (only for non-cancer participants) Individuals scheduled to undergo chest and/or abdominal CT or MRI imaging.

Exclusion Criteria6

  • Pregnancy (self-reported pregnancy status).
  • Individuals for whom blood collection is deemed difficult by the investigator.
  • Individuals with a history of infection with HIV, HTLV, or syphilis.
  • (only for non-cancer participants) Individuals diagnosed with another malignancy within the past 5 years (exceptions: non-melanoma skin cancer, in-situ malignancies, thyroid cancer, and cervical intraepithelial neoplasia treated with curative intent).
  • (only for non-cancer participants) Individuals with cancer of unknown primary origin.
  • (only for non-cancer participants) Individuals with synchronous or metachronous multiple primary cancers.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Yonsei Cancer Center

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07598747


Related Trials